Zacks Research Upgrades DBV Technologies (NASDAQ:DBVT) to "Hold"

Key Points

• Zacks Research upgraded DBV Technologies from a "strong sell" to a "hold" rating, reflecting a slight change in market sentiment.
• Despite the upgrade, other analysts have varying opinions, with one recent downgrade to a "sell" and a consensus rating of "Moderate Buy".
• DBV Technologies reported a significant earnings miss, with a net margin of -3,220.49% and a projected earnings per share of -7.05 for the current year.

DBV Technologies (NASDAQ:DBVT - Get Free Report) was upgraded by Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued on Monday,Zacks.com reports.

Several other equities analysts also recently issued reports on DBVT. Wall Street Zen downgraded shares of DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. JMP Securities reissued a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a research note on Thursday, June 26th. Finally, Lifesci Capital raised shares of DBV Technologies to a "strong-buy" rating in a research note on Thursday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $14.75.

DBV Technologies Price Performance

DBVT stock opened at $10.00 on Monday. The company's 50 day simple moving average is $9.55 and its 200-day simple moving average is $8.94. The firm has a market capitalization of $273.95 million, a PE ratio of -2.10 and a beta of -0.36. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $12.78.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34). The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $0.64 million. DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. As a group, sell-side analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

A number of large investors have recently bought and sold shares of the stock. Vivo Capital LLC purchased a new position in DBV Technologies during the second quarter worth approximately $9,659,000. Adage Capital Partners GP L.L.C. purchased a new position in DBV Technologies during the second quarter worth approximately $9,659,000. MPM Bioimpact LLC purchased a new position in DBV Technologies during the second quarter worth approximately $9,649,000. Octagon Capital Advisors LP purchased a new position in shares of DBV Technologies in the 2nd quarter valued at $9,315,000. Finally, Nan Fung Trinity HK Ltd. purchased a new position in shares of DBV Technologies in the 2nd quarter valued at $340,000. Hedge funds and other institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.